Objective: To determine the extent to which high-dose (30mg) oral montelukast, added to standard treatment in children with moderate and severe acute exacerbations improves outcomes.
Central Hypothesis: High-dose oral montelukast, added to standard treatment in children aged 5 to 17 years with moderate and severe acute asthma exacerbations, rapidly improves lung function, clinical severity, hospitalization rate and 72-hour symptom burden.
Secondary Hypotheses:
There are greater effects of high-dose oral montelukast on lung function and on the secondary outcomes in the presence of respiratory viral detection or leukotriene-mediated inflammation; and
There is an interaction between viral detection and urinary leukotriene 4 level with treatment-response.
Design: A two-arm, parallel randomized controlled trial of high-dose oral montelukast versus identical placebo, as add-on to standard treatment, in children aged 5 to 17 years with moderate and severe acute asthma exacerbations.
Intervention: High-dose oral montelukast added to standard treatment in comparison with standard treatment as the 2nd treatment-allocation arm.
Primary and Important Secondary Endpoints: For the Primary Aim, the primary outcome measure to be compared between arms will be change of %-predicted airway resistance by impulse oscillometry (IOS) at 5Hz (%R5) at 2 hours after treatment initiation. Secondary outcomes will include improvement of %-predicted FEV1 (%FEV1), clinical severity measured using the validated Acute Asthma Intensity Research Score (AAIRS), hospitalization rate, and 72 hour symptom burden using the Pediatric Asthma Caregiver Diary (PACD). For the Secondary Aim, the investigators will determine (1) The effects of high-dose oral montelukast on lung function and on our secondary outcomes in the presence of nasal viruses and of greater leukotriene-mediated inflammation; and (2) The degree of interaction between viral detection and urinary leukotriene E4 (LTE4) level with treatment-response.
Laboratory evaluations: The primary outcome (change of %R5) and select secondary outcomes (%FEV1, AAIRS, LTE4) will be measured before and again at 2 hours after treatment initiation. The other secondary outcomes will be measured at the time of hospitalization decision-making by the clinical team (hospitalization rate) or at 72-hours after treatment initiation (PACD).

开始日期2025-09-01

申办/合作机构

Vanderbilt University Medical Center

NCT06360185 / Not yet recruitingN/AIIT

Retrospective Study Investigating the Clinical Characteristic of Patients With Acute Presentation for Asthma to the A+E Department in a Busy Acute Hospital in England UK in Era of Biological Therapy for Asthma Between January 2019 and January 2024

Study team will obtain a list of all patients who have been seen in A+E over the past 6 years with a discharge diagnosis of asthma. Their history will be reviewed from their A+E notes. Team will obtain weight and height from Electronic prescribing tool and will obtain compliance information and past medical history from participant's GP records. Team will use participant's postcode to word out socio economic status quintile using office of national statistics tool. The following information will be taken from hospital documentation and from GP records.

开始日期2024-05-01

申办/合作机构

Norfolk & Norwich University Hospitals NHS Foundation Trust

NCT06377345 / Not yet recruitingN/A

Remote Patient Monitoring Solution for Chronic Respiratory Disease Management

Aim: To evaluate the use of AeviceMD Monitoring System (AeviceMD) asthma in reducing acute exacerbation.
Methodology: Using a randomized controlled trial design, this project aims evaluate the effectiveness of AeviceMD in improving patients' outcomes in terms of reducing exacerbation, healthcare utilization, improving quality of life, self-efficacy, and cost effectiveness. Paediatric patients above age 7 and adults will be recruited. The data follow-up period is 3 months. It will also evaluate the usability of the device from both patients' and clinicians' perspective. 180 patients (124 adults, 56 pediatrics) and 120 clinicians will be recruited.
Importance of study: This study will evaluate if the AeviceMD can help improve disease management and reduce recurrence of asthma exacerbation.
Potential benefits and risk: AeviceMD allows for remote monitoring and tracking of patients' lung sounds, which could be used by patients to monitor their lung condition and prevent an episode of exacerbation or worsening exacerbations culminating in an admission which who further utilize already limited healthcare resources. An exacerbation is an episode of severe shortness of breath, cough, and chest tightening which warrants a visit to a healthcare institution. Through self-monitoring, patients can be empowered to self-manage their asthma, with aid of the asthma action plan which is given to all patients with asthma. AeviceMD can also help provide clinicians with patients' objective lung data. In the primary care setting, care is also fragmented as patients are often followed-up by a different doctor or healthcare providers. Clinicians have no objective data to track patients, and is dependent on patients' self-report and possible recall bias. There is no expected risk with the use of the device.

开始日期2024-04-20

申办/合作机构-

100 项与急性哮喘相关的临床结果

登录后查看更多信息

100 项与急性哮喘相关的转化医学

登录后查看更多信息

0 项与急性哮喘相关的专利（医药）

登录后查看更多信息

4,227

项与急性哮喘相关的文献（医药）

2024-11-01·Journal of Asthma

The role of 14-3-3β in acute asthma in children and analysis of the risk factors for asthma exacerbation

Article

作者: Li, Aijun ; Xie, Xueli ; Dong, Junjun ; Zhang, Yanli ; Li, Shufang ; Yang, Qiuyan ; Xiong, Xiaoman

OBJECTIVETo investigate the role of 14-3-3β in acute asthma exacerbations in children and analyze the risk factors for asthma exacerbations.METHODSThis study recruited 101 children with acute asthma exacerbations, 101 children with stable asthma, and 65 healthy children. Serum 14-3-3β was compared among the three groups. Factors such as asthma family history, skin prick test, serum-specific IgE test, coinfections, and clinical indicators (FeNO, FEV1, white blood cells, eosinophils, and serum IgE level) were compared between the asthma groups. Risk factors associated with acute asthma exacerbations were identified using multivariate logistic regression models. ROC curve was drawn to determine the diagnostic sensitivity and specificity of 14-3-3β.RESULTSSerum 14-3-3β was significantly greater in the acute asthma group than in the stable asthma and control groups. Serum 14-3-3β was higher in severe acute asthma group than in mild-moderate asthma group. There were no significant differences in serum 14-3-3β levels between stable asthma and control groups (p > .05). Multivariate logistic regression analysis revealed that serum 14-3-3β level, FeNO, coinfection, and FEV1 z-score significantly increased the odds of acute asthma exacerbations in children. The optimal 14-3-3β cutoff value (39.79 ng/mL), had a sensitivity of 69.3% and specificity of 94.1% for predicting acute asthma exacerbations.CONCLUSIONS14-3-3β is elevated in children with acute exacerbations of asthma, and increases with exacerbation severity. 14-3-3β, FeNO, FEV1, and coinfection could be independent risk factors for predicting asthma exacerbations. The optimal 14-3-3β cutoff value for predicting asthma exacerbations was 39.79 ng/mL.

2024-11-01·Jornal de Pediatria

Inhaled MgSO4 in acute asthma: are we on the right course?

Letter

作者: Amantéa, Sérgio Luís

2024-10-02·Journal of Asthma

Expert panel consensus recommendations on the utilization of nebulized budesonide for managing asthma and COPD in both stable and exacerbation stages in Thailand

Review

作者: Limsukon, Atikun ; Wiwatcharagoses, Kittiyaporn ; Kawamatawong, Theerasuk ; Reechaipichitkul, Wipa ; Domthong, Pornanan ; Saiphoklang, Narongkorn ; Sanguanwit, Pitsucha ; Kornthatchapong, Kumpol ; Maneechotesuwan, Kittipong ; Sewatanon, Tirachat ; Chiewchalermsri, Chirawat ; Rattanawongpaibul, Akrawat ; Wongsurakiat, Phunsup

OBJECTIVEThis study investigated the utilization of nebulized budesonide for acute asthma and COPD exacerbations as well as for maintenance therapy in adults.DATA SOURCESWe conducted a search on PubMed for nebulized budesonide treatment.SELECTED STUDIESSelecting all English-language papers that utilize Mesh phrases "asthma," "COPD," "budesonide," "nebulized," "adult," "exacerbation," and "maintenance" without temporal restrictions, and narrowing down to clinical research such as RCTs, observational studies, and real-world studies.RESULTSAnalysis of 25 studies was conducted to assess the effectiveness of nebulized budesonide in asthma (n = 10) and COPD (n = 15). The panel in Thailand recommended incorporating nebulized budesonide as an additional or alternative treatment option to the standard of care and systemic corticosteroids (SCS) based on the findings.CONCLUSIONNebulized budesonide is effective and well-tolerated in treating asthma and COPD, with less systemic adverse effects compared to systemic corticosteroids. High-dose nebulized budesonide can enhance clinical outcomes for severe and mild exacerbations with slow systemic corticosteroid response. Nebulized budesonide can substitute systemic corticosteroids in some situations.

项与急性哮喘相关的新闻（医药）

2024-09-19

·赛柏蓝

长风药业闪亮登场“中华医学会2024年变态反应学术会议”

中华医学会2024年变态反应学术会议海报由中华医学会、中华医学会变态反应学分会主办，广东省医学会承办，广州医科大学附属第一医院、广东省人民医院、中山大学附属第三医院、中山大学附属第一医院、广州医科大学附属第二医院协办的中华医学会2024年变态反应学术会议9月12日-9月14日于广州顺利召开。会议开幕式盛况中华医学会变态反应学分会主任委员程雷教授担任大会主席。本次全国变态反应学术会议为期两天，是国内变态反应学科水平最高、规模最大的学术会议。为学科各领域内专家、学者、医务工作搭建了分享知识、交流经验、探讨学科进展的重要平台。本次会议通过专题会、学术报告、晨间教育、病例分享、专家座谈、圆桌讨论、辩论赛、壁报等多种学术形式，全方位展示了我国变态反应学科最新研究成果和实践案例。金秋九月，岭南丹桂飘香、热情似火，全国各地的变态反应医生齐聚广州，探讨学科内各个领域的最新研究进展、交流学科前沿进步，推动我国变态反应学科不断发展壮大，向前进步。会议现场盛况诸多变态反应领域大咖、临床医生齐聚一堂，共襄盛会本次变态反应会中，北京协和医院与西安交通大学第一附属医院榆林医院共同发表的《氮䓬斯汀氟替卡松鼻喷雾剂预防性治疗花粉症的随机对照研究》登上了大会壁报墙，引领了国内关于氮䓬斯汀氟替卡松复方制剂在预防领域的研究。本文第一作者是崔乐与高娜，通讯作者为关凯、郝文东。众所周知，花粉则是世界范围内最常见、最重要的气传致敏原。春季的树木、秋季的杂草能引发过敏。这些植物的花粉，经自然风而非虫媒传播，花期长、花粉量大、质量轻，一些花粉的飘散水平距离能达数十甚至上百公里，垂直方向可达上万米的高空。《中国花粉致敏树种分级研究》中提到，中国文献明确记录的致敏树种总计83种。花粉困扰了千千万万的中国患者。每当季节到来时，患者总会频繁的鼻痒、不停地打喷嚏、持久的鼻塞，不间断的流涕，甚至眼痒、流眼泪，严重影响了患者工作、生活。在花粉季到来之前用药预防一直是临床中热议的问题，可以确定的是，预防性治疗有利于控制患者在花粉季节中的鼻部症状。然而，关于联合使用鼻用糖皮质激素和鼻用抗组胺药预防性治疗花粉症的研究很少。协和医院联合榆林医院的联合发起了使用氮草斯汀氟替卡松鼻喷雾剂舒霏敏®进行预防性治疗的临床试验，评估其对花粉症患者鼻部症状和哮喘急性发作的作用。研究结果显示：提前两周使用氮䓬斯汀氟替卡松鼻喷雾剂无论在花粉播散期或是两组同时用药期，预防治疗组的鼻部症状总评分均显著低于常规治疗组，预防治疗组哮喘发作率低于常规治疗组，但未达到统计学显著性。使用氮䓬斯汀氟替卡松鼻喷雾剂舒霏敏®预防性治疗蒿属花粉过敏的患者可以缓解其在花粉季节中的鼻部症状，并可能减少哮喘急性发作。崔乐等发表的《氮䓬斯汀氟替卡松鼻喷雾剂预防性治疗花粉症的随机对照研究》文章荣登壁报墙 2022年11月，国内首个氮䓬斯汀氟替卡松鼻喷雾剂舒霏敏®的上市，给国内变应性鼻炎临床治疗带来了全新的选择，而今关于舒霏敏®预防性治疗试验结果的披露，更加为我国广大的花粉症患者带来福音，提前用药，控制症状，拥抱生活。长风药业携产品亮相会议现场长风药业亮相“中华医学会2024年变态反应学术会议”会场长风药业长风药业始终伴随变态领域发展，为临床提供变应性鼻炎、哮喘等疾病一体化治疗及管理方案，同时不断创新，加大研发投入，与变态反应学科共成长。本次会议上，长风药业携旗下呼吸系统疾病一体化治疗及管理方案的相关产品亮相会议展台，其中包括舒霏敏®(氮䓬斯汀氟替卡松鼻喷雾剂)，畅起®(吸入用布地奈德混悬液)，畅霖®(硫酸特布他林雾化吸入用溶液)，畅抒®(吸入用硫酸沙丁胺醇溶液)等相关产品。 01 舒霏敏®(氮䓬斯汀氟替卡松鼻喷雾剂) 新型国产复方制剂舒霏敏®(氮䓬斯汀氟替卡松鼻喷雾剂)是国内首个激素-抗组胺药鼻喷制剂。舒霏敏®于2022年末成功上市，标志着我国AR临床治疗拥有了全新的复方制剂选择，上市一年后，成功纳入2023年版国家医保目录，将惠及更广泛的AR患者。舒霏敏®在一次喷雾中提供两种一线药物，被各类国际、国内指南推荐其用于治疗常年性和季节性变应性鼻炎，治疗效果优于单方治疗，具有疗效更强、安全性更好、依从性更佳、独特玫瑰芬芳四大优点。如今，舒霏敏®已进入临床近两年，得到临床专家的广泛好评，其治疗变应性鼻炎起效更快，疗效更强，一次喷雾包含两种药物更可以提高患者用药的依从性。 02 畅起®(吸入用布地奈德混悬液) 畅起®(吸入用布地奈德混悬液)是一种具有高效局部抗炎作用的吸入用糖皮质激素(ICS)，通过雾化器吸入给药，同时也是目前唯一批准可用于4岁及以下儿童的ICS。可用于支气管哮喘的治疗，替代或减少口服类固醇治疗，是防治哮喘等呼吸道疾病的指南推荐药物，具有起效快，给药剂量小、不良反应相对较小等优点。 03 畅抒®(吸入用硫酸沙丁胺醇溶液) 畅霖®(硫酸特布他林雾化吸入用溶液) 沙丁胺醇与特布他林均为高选择性的短效β2受体激动剂(SABA)中的代表药物。SABA选择性的与支气管平滑肌表面的β2受体结合，松弛支气管平滑肌，缓解呼吸道痉挛。SABA可以通过雾化器吸入给药，可以在几分钟内迅速缓解支气管痉挛。对于严重的急性哮喘发作的治疗、AECOPD等的治疗，具有起效迅速、效果好、不良反应小的特点，是GINA、GOLD、《中国支气管哮喘防治指南》等指南的推荐药物。沙丁胺醇和特布他林的主要区别在于：01.特布他林的持续作用时间更长[1]，而沙丁胺醇的起效速度更快，在一些非常急症的情况下，首选沙丁胺醇治疗[2][3][4]。02.特布他林很少经母乳排泄，因此可作为哺乳期妇女优选的SABA[5]；03.特布他林对β2受体的选择性强于沙丁胺醇，心血管不良事件风险更低，心率过快或合并心血管疾病的患者，有专家共识推荐首选特布他林[6]；04.特布他林不仅能扩张支气管，还能增加黏液纤毛的清洁功能，从而加速黏液分泌物的清除，所以对于治疗合并浓痰和粘液分泌过多的患者，效果更好，可以作为首选[7]。与会专家在长风展台了解、试用相关产品，合影留念与会专家热情高涨，纷纷前往长风展台了解、试用产品。很多医生带着对舒霏敏®的期待前来交流、探讨，并表示舒霏敏®的上市解决了临床之所需，患者之所困，是一款真正的好产品，称得起国产药品的骄傲。医生纷纷表明，期待长风药业为变态反应领域提供更多、更便捷的一体化治疗及管理方案，为广大患者带去福音。 [1] Nials AT, Coleman RA, Johnson M, Magnussen H, Rabe KF, Vardey CJ. Effects of beta-adrenoceptor agonists in human bronchial smooth muscle[J]. Br J Pharmacol. 1993 Nov;110(3):1112-6. [2] 成人慢性气道疾病雾化吸入治疗专家组. 成人慢性气道疾病雾化吸入治疗专家共识 [J]. 中国呼吸与危重监护杂志,2012,11(2):105-110. [3] 中华医学会临床药学分会《雾化吸入疗法合理用药专家共识》编写组. 雾化吸入疗法合理用药专家共识 (2019 年版)[J]. 医药导报,2019,38(2):135-146. [4] 冯玉麟.成人慢性气道疾病雾化吸入治疗专家共识[J].中国呼吸与危重监护杂志,2012,11(2):105-110 [5]American Academy of Pediatrics Committee on Drugs．Thetransfer of drugs and other chemicals into human milk［J］．Pediatrics，2001，108( 3) : 776－789. [6] 中国医师协会急诊医师分会,中国人民解放军急救医学专业委员会,等.雾化吸入疗法急诊临床应用专家共识（2018）[J].中国急救医学,2018,38(7):565-574. [7] 硫酸特布他林雾化吸入溶液说明书 END 长风药业 —BREATHE EASIER, LIVE BETTER— 向上滑动阅读全文长风药业以提高人类的生命质量和健康水平为己任，以开发高质量的呼吸系统用药为目标，致力于研发、生产和销售具有安全、有效、惠及大众的各类吸入制剂药物。公司建立了覆盖吸入气雾剂、吸入粉雾剂、吸入液体制剂、吸入喷雾剂、鼻喷雾剂、脂质体在内的多剂型研发管线。希望成为集呼吸系统药物研发、产业化和商业化为一体的行业知名药企。声明：此篇文章受众仅为医药、医疗等健康产业专业伙伴，仅供医学药学专业人士使用，不针对普通消费大众。

2024-06-25

·BioSpace

Ethris Announces Positive Initial Phase 1 Data Demonstrating Nasal Delivery of mRNA Lead Candidate ETH47

ETH47 resulted in a dose-dependent increase in target protein expression in the nasal cavity Nasal administration of ETH47 was generally safe and well-tolerated, with no severe adverse events or drug-related adverse events of clinical relevance Full data readout expected in the third quarter of 2024 Following the Phase 1 study, Ethris plans to advance ETH47 for patients with uncontrolled asthma MUNICH--(BUSINESS WIRE)-- Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced today preliminary positive data from its Phase 1 dose escalation clinical trial evaluating the safety, tolerability, and target engagement of lead mRNA candidate ETH47 encoding interferon lambda (IFNλ), in healthy participants. IFNλ has a key role in viral immunity in the respiratory tract. The data indicates that ETH47, administered nasally, was generally safe and well-tolerated, with no severe adverse events or drug-related adverse events of clinical relevance across all dose levels. Initial results also show target engagement and suggest no systemic biodistribution of ETH47. A full data readout is planned for the third quarter of 2024. “These preliminary results are highly encouraging as they provide the first clinical validation of our innovative SNIM®RNA platform and SNaP LNP technology, which allows localized administration directly at virus entry sites and supports the potential of ETH47 as a broadly protective antiviral candidate for respiratory diseases,” said Dr. Thomas Langenickel, Chief Medical Officer of Ethris. “We look forward to sharing comprehensive Phase 1 data later this year as we continue evaluating ETH47 for the treatment of uncontrolled asthma. Furthermore, successful nasal delivery opens up mRNA therapeutics as a new potential modality to treat diseases of the respiratory tract.” Uncontrolled asthma is a significant burden for patients, including 4.4 million moderate to severe asthma patients in the US alone. Approximately 80% of acute asthma attacks (exacerbations) are associated with virus infections. Susceptibility to viral infections in asthma is associated with dysregulation of IFNλ in asthmatics. The promising safety and tolerability pro ETH47 observed in the clinical trial, along with its potential to enhance mucosal immune defense and correct low IFNλ levels, could represent a significant advancement in the treatment landscape for uncontrolled asthma. Professor Eric Bateman, MD, Key Opinion Leader and Member of the Board of the Global Initiative for Asthma (GINA) said, “Given the strong association between viral infections, particular with rhinovirus, and asthma exacerbations, Ethris’ mRNA product candidate ETH47, with its unique mechanism of action has the potential to fill a significant gap in the asthma treatment paradigm.” The Phase 1 trial is a randomized, placebo-controlled, double-blind, single-ascending dose design to evaluate the safety and tolerability of ETH47 in healthy participants. ETH47, Ethris’ lead candidate developed using the company’s proprietary technologies was designed to address the unique challenges of delivering mRNA to the lungs, including physiological barriers, low transfection efficiency and delivery vehicle-induced inflammatory responses. This initial data assessment indicates proof of principle with ETH47 and supports its continued development toward human viral challenge studies, including a rhinovirus challenge study in mild asthmatics. About Ethris Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients’ lives. For more information, visit . View source version on businesswire.com: Contacts For Ethris, please contact: Dr. Philipp Schreppel +49 89 244 153 042 schreppel@ethris.com Source: Ethris GmbH View this news release online at:

临床1期疫苗信使RNA临床结果siRNA

2024-06-18

·BioSpace

Ethris Announces $5 Million in Funding to Prepare Lead Candidate ETH47 for Phase 2 Study

Ethris has received $5 million in funding from The Bill & Melinda Gates Foundation to support preparations for ETH47’s Phase 2a study including CMC manufacturing processes ETH47 is Ethris' first-in-class inhaled mRNA-based candidate with the potential to address a broad spectrum of chronic respiratory diseases and emerging respiratory infections and is currently being evaluated in a Phase 1 clinical trial MUNICH--(BUSINESS WIRE)-- Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, announced today that it has received funding from the Gates Foundation to support the advancement of the company’s lead mRNA-based product candidate, ETH47. This funding of $5 million includes an equity investment component expected to close at the company’s next financing round. The new capital will enable the company to rapidly reach Phase 2 readiness and build out the CMC manufacturing process for the next clinical trial. “Ethris’ lead mRNA-based product candidate ETH47 was designed to have broad antiviral capabilities, placing it in a distinct position to address a range of virus-induced respiratory infections and chronic respiratory diseases. Ethris, supported by the new funding from the Gates Foundation, will accelerate its clinical development, initially targeting asthma exacerbations, an indication with a high unmet medical need where approximately 80% of acute asthma attacks are associated with virus infections. We are grateful for the foundation's support in our mission to combat the global burden of current and emerging respiratory infections by harnessing the full scope of ETH47's virus-agnostic potential,” said Dr. Carsten Rudolph, CEO of Ethris. A Phase 1 study is ongoing with Ethris’ inhaled mRNA candidate ETH47 to evaluate safety, tolerability, and target engagement in healthy participants. A full data readout is planned for the third quarter of 2024. The ETH47 program is also supported by the BayTherapie2020 program, an initiative of the German state of Bavaria. About ETH47 ETH47 is Ethris’ first-in-class mRNA-based product candidate encoding type III interferon (IFN) that was developed using the company’s Stabilized Non-Immunogenic mRNA (SNIM®RNA) platform, and uniquely designed to be administered locally to the lung through inhalation or nasal spray using Ethris’ proprietary Stabilized NanoParticle (SNaP) LNP platform. ETH47 is meant to induce a mucosal innate immune defense response at virus entry sites as well as inhibit viral replication. ETH47’s versatile, virus- and mutation-independent mode of action has the potential to address virus-driven exacerbation of chronic respiratory diseases like asthma as well as seasonal and emerging respiratory virus infections. About Ethris Ethris, a clinical stage biotech company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients’ lives. For more information, visit View source version on businesswire.com: Contacts For Ethris, please contact: Dr. Philipp Schreppel +49 89 244 153 042 schreppel@ethris.com Source: Ethris GmbH View this news release online at:

临床1期信使RNAsiRNA疫苗临床2期